Advancing Liver Health in a Shifting Global Landscape: Nat Re Gastro & Hepatol | July 2026
Introduction:
Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent need for coordinated global strategies to improve liver health and reduce inequities in prevention, diagnosis, and care.
Key Takeaways:
- The World Health Assembly has officially recognized steatotic liver disease (SLD) as a major non-communicable disease, marking a historic milestone for global liver health.
- MASLD affects an estimated 1.3 billion people worldwide, with the global burden expected to increase substantially by 2050.
- MetALD (Metabolic and Alcohol-Related Liver Disease) is increasingly recognized as an important contributor to liver-related morbidity, particularly in Europe.
- Despite progress, viral hepatitis remains a major global health challenge, and the WHO 2030 elimination targets are unlikely to be achieved without stronger implementation.
- Encouragingly, new HBV infections and hepatitis C-related deaths continue to decline, reflecting the impact of vaccination and antiviral therapies.
- Healthcare inequities, limited access to prevention and treatment, and armed conflicts remain major barriers to improving liver health worldwide.
- Integrating liver disease into national non-communicable disease (NCD) strategies is essential to reduce liver-related mortality, hepatocellular carcinoma, and cardiometabolic complications.
Clinical Impact:
This editorial emphasizes that liver health should no longer be viewed in isolation. Prevention of MASLD, alcohol-related liver disease, viral hepatitis, and liver cancer requires coordinated public health policies, equitable access to care, and integration into broader cardiometabolic and NCD programs.
Bottom Line:
Global liver health is at a turning point. While recognition of steatotic liver disease as a major NCD represents a landmark achievement, accelerating prevention, expanding access to care, and reducing global health inequities will be critical to lowering the future burden of liver disease.
